
The FDA Is Moving Past Animal Testing. Here’s How Ncardia Helps Make It Happen
        
      
      
      
        
Press release: Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
        
      
      
      
        
Ncardia Acquires STAR-CRISPR Technology for Advanced Gene Editing of iPSCs
        
      
      
      
        
Unveiling Ncardia's Path to Innovation and Growth
        
      
      
      
        
The Urgent Need for Reliable Cell Models in ALS Research
        
      
      
      
        
Ncardia's Remarkable Journey in 2023
        
      
      
    